πŸ‡ΊπŸ‡Έ FDA
Patent

US 9585921

Compositions and methods

granted A61KA61K35/37A61K35/74

Quick answer

US patent 9585921 (Compositions and methods) held by Seres Therapeutics, Inc. expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Seres Therapeutics, Inc.
Grant date
Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K35/37, A61K35/74, A61K35/741, A61K35/742